Drug intelligence / Profile preview

mRNA-1975 + mRNA-1982

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

mRNA-1975 + mRNA-1982 is an investigational combination of two mRNA-based vaccines developed by Moderna for the prevention of Lyme disease. The vaccines utilize messenger RNA encapsulated in lipid nanoparticles to encode the outer surface protein A (OspA) antigens of *Borrelia* bacteria. mRNA-1982 is a monovalent vaccine targeting serotype 1 (*Borrelia burgdorferi*), while mRNA-1975 is a heptavalent vaccine covering serotypes 1 through 7, providing broad protection against the major *Borrelia* species prevalent in North America and Europe. The mechanism of action is unique as a transmission-blocking vaccine; antibodies generated in the human host are ingested by the tick during a blood meal, where they kill the *Borrelia* pathogens in the tick's midgut before they can migrate to the salivary glands and infect the human. The combination is currently in Phase I/II clinical development (NCT05975099).

Other names: mRNA-1975 + mRNA-1982

Targets

OspA (Outer surface protein A)

Beyond the preview

Go deeper on mRNA-1975 + mRNA-1982.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1975 + mRNA-1982.

Explore the full profile